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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2014, TaiwanAbstract Aloin, the major anthraquinone in aloe exudates and gels, has been shown to be an
effective antioxidant and anti-inflammatory agent. We studied the antitumor effects of aloin
in human non-small cell lung cancer cells. The treatment of lung cancer cells with aloin sup-
pressed cell growth in a time- and concentration-dependent manner. Aloin-induced apoptosis
also showed a concentration-dependent behavior when studied by flow cytometry. In addition,
autophagy occurred after treatment with aloin. Taken together, our data demonstrate that
aloin induces apoptosis and autophagy in human lung cancer cells. Aloin is therefore a poten-
tial therapeutic agent for human lung cancer and is worthy of further investigation.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Lung cancer is the most common cause of cancer-related
death worldwide and is classified as either small cell lung
cancer (SCLC) or non-small cell lung cancer (NSCLC). NSCLCnt of Medical Laboratory
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Genomic Medicine and Biomarkeraccounts for 75e80% of patients with primary lung cancer.
Compared with NSCLC, SCLC shows an aggressive behavior
with rapid tumor growth and early spread to distant sites;
its malignancy is the highest of all types of lung cancer.1e3
Surgery is the most effective therapeutic modality, but the
postoperative prognosis remains poor. In addition, most
patients present with advanced stage disease and chemo-
therapy with or without radiotherapy is recommended.
Although NSCLC and SCLC have a relatively good initial
response to clinical treatment, relapse or disease progres-
sion may occur quickly and the prognosis for these patientsSociety. Published by Elsevier Taiwan LLC. All rights reserved.
Aloin suppresses growth of lung cancer cells 145remains poor.2,3 A novel and effective treatment for SCLC
and NSCLC is therefore needed.
Aloin, alsoknownasbarbaloin,4 is themajoranthraquinone
in aloe exudates and gels and has been characterized as the C-
glycoside of aloe-emodin.5,6 Aloin is a potent inhibitor of
tyrosinase and is an effective inhibitor of stimulated gran-
ulocyte matrix metalloproteinases.7,8 Aloin also protects
against chemically induced colon toxicity and has been re-
ported to act by increasing antioxidant levels and by having
anti-inflammatory and antiproliferative effects.9 Aloin has
been shown to cause a pronounced reduction in cell prolifer-
ation and has also been shown to induce cell apoptosis in
HeLaS3 cells.10 At higher concentrations, it has caused a
reduction in the proportion of cells undergoing mitosis by the
induction of apoptosis, inhibition of topo II and protein
expression, and the downregulation of cyclin B1 protein
expression in MCF-7 cell lines.11 The treatment of breast and
ovarian tumor cells with aloin showed a persistent aneuploid
pattern and a significantly dose-dependent increase in the
percentage of the S phase fraction and in the proportion of
cells cycling at a higher ploidy level.12 Importantly, a loss of
cell membrane integrity was preceded by a loss of mitochon-
drial membrane potential after treatment with aloin, sug-
gestingamitochondrial-dependentpathway for aloin-induced
apoptosis.13 The combined treatment of cells with aloin and
low doses of cisplatin increases the antiproliferative activity
of aloin.14 Aloin may also inhibit tumor angiogenesis and
growth via blocking STAT3 activation and has resulted in sub-
stantially reduced tumor volumesandweights in in vivomouse
xenografts without obvious toxicity.15 Aloin could therefore
be a novel anticancer agent in a number of cancers. However,
the antitumor behavior of aloin in lung cancer cells has not yet
been clearly elucidated.
This study showed that aloin can suppress the growth of
human NSCLC cells. Apoptosis and autophagy were also
observed after treatment with aloin. Our data therefore
suggest that aloin can be used as an anticancer agent in
human NSCLC.Materials and methods
Lung cancer cell lines and cell culture
TheH1299 cellsweremaintained in RPMI1640medium (Gibco
BRL, Grand Island, NY, USA) and the A549 cells were grown in
Dulbecco’sModified EagleMedium (Gibco)with 10% fetal calf
serum (Gibco) and 1% penicillin/streptomycin (Gibco); they
were incubated at 37C in 5% carbon dioxide. A549 contains
wild type p53. H1299 contains null deletion p53.Cell proliferation assay
Aloin was purchased from SigmaeAldrich (St Louis, MO,
USA). A549 or H1299 cells (5  103/well) were plated into
96-well tissue culture plates and grown in the specified
medium. The cells were treated with medium only (the
negative control) or medium containing aloin
(12.5e400mM). After incubation for 72 hours, metabolically
active cells were determined by 3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyl tetrazolium bromide (MTT) assay. Threeindependent experiments were analyzed statistically to
give the final result.
Measurement of multinucleated cells
Cells were treated with or without aloin for 72 hours. The
nuclei were stained with 40,6-diamidino-2-phenylindole
(DAPI) (Sigma) for 20 minutes at room temperature. The
morphology of cells with multiple nuclei (2 or more nuclei
in 1 cell) was confirmed under a fluorescent microscope and
compared with the observations obtained with light
microscopy.
Apoptosis analysis
For the cells treated with or without aloin, Annexin-V
staining (SigmaeAldrich) was performed to detect
apoptotic cells. The cells were washed twice with
phosphate-buffered saline and the cell pellets were resus-
pended in a staining solution of Annexin-V-fluorescein iso-
thiocyanate and propidium iodide (PI) and incubated for 15
minutes at room temperature in darkness. The Annexin-V or
PI fluorescent intensities were analyzed by guava easy-
Cyte flow cytometers (Merk Millipore, Germany); 10,000
cells were evaluated in each sample.
Western blot analysis of LC3-II expression
The induction of autophagy by aloin was evaluated by the
expression of LC3-II using Western blot analysis (antibody
purchased from Medical & Biological Laboratories Co.,
Nagoya, Japan). The expression of beta-actin (antibody
purchased from Cell Signaling Technology, Inc., USA.) was
used as an internal control.
Results
Aloin inhibition of cell growth of human lung cancer
cells
Two human NSCLC cell lines, A549 and H1299, were used to
evaluate the inhibition of cell growth after treatment with
aloin. The cellular viability was determined by MTT assay.
As shown in Fig. 1, the cell viability decreased significantly
in a concentration-dependent manner in these two cell
lines. The IC50 of aloin in A549 and H1299 cells was about
150mM and 200mM after 72 hours of treatment, respectively
(Fig. 1). These data show that aloin can suppress the growth
of NSCLC cells in vitro.
Aloin induction of multinucleated cells in human
NSCLC cells
The formation of giant multinucleated cells is a phenotype
of mitotic catastrophe induced by ionizing radiation
or certain anticancer drugs.16 Aloin has previously been
reported to induce aneuploid and increased S phase
populations in human ovarian and breast cancer cells.12 We
therefore investigated whether aloin induced multi-
nucleation in our two cell lines. As shown in Fig. 2A, cells
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Figure 1 Aloin inhibition of the growth of human non-small
cell lung cancer cells. Cells were incubated with different
concentrations of aloin for 48 hours or 72 hours and the cellular
viability of A549 and H1299 cells was analyzed using the
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide
assay. All the data are expressed as mean  SEM values for
three independent experiments.
146 M.-C. Lee et al.containing an enlarged phenotype could be observed by
microscopy after treatment with aloin. This phenomenon
was confirmed by DAPI staining, which showed the presence
of multinucleated cells in the groups treated with aloin
(Fig. 2B). Aloin therefore induces the formation of multi-
nucleated cells in human NSCLC cell lines.Figure 2 Aloin-induced formation of multinuclear cells in huma
100mM or 200mM aloin for 72 hours and the cellular morphology was
200mM aloin for 72 hours and the cellular nuclei were stained by 4
microscopy. The multinuclear cells are indicated by arrows.Aloin induction of apoptosis in human NSCLC cells
To confirm whether aloin induced apoptosis in human NSCLC
cells, cellswere incubated inmediumormediumwithaloin for
24 hours, 48 hours, and 72 hours, and the apoptotic cells were
then determined by flow cytometry. As shown in Fig. 3A, after
treatment with aloin (200mM), the percentages of apoptotic
cells in human A549 cells at 24 hours, 48 hours, and 72 hours
were 3.14%, 4.6%, and 27.04%, respectively. The percentage
of apoptotic cells in human H1299 cells after treatment with
aloin (200mM) at 24 hours, 48 hours, and 72 hours were 1.06%,
0.49%, and 8.58%, respectively (Fig. 3B). These data show that
aloin-induced apoptosis in lung cancer cells occurred at con-
centrations of about 200mM with a 72 hour treatment. A549
cells were more susceptible to aloin-induced apoptosis than
H1299 cells.
Changes in LC3-II expression level after treatment
with aloin in human NSCLC cells
We also investigated whether autophagosome was formed
in human NSCLC cells during treatment with aloin. Cells
were treated with either medium or medium with aloin and
the expression of LC3-II, a marker of autophagosome,17e22
was determined by Western blotting. As shown in Fig. 4,
after treatment with aloin (100mM or 200mM) for 72 hours,
the expression of LC3-II in A549 cells was increased on
treatment with 100mM aloin, but reduced on treatment
with 200mM aloin. However, LC3-II expression in H1299 cells
was reduced in a concentration-dependent manner. These
results suggest that the formation of autophagosome by
aloin induction may be an anti-apoptosis effect in A549
cells at lower concentrations (100mM). However, 72 hours of
treatment at the higher concentration (200mM) inducedn non-small cell lung cancer cells. (A) Cells were treated with
observed with microscopy. (B) Cells were treated with 100mM or
0,6-diamidino-2-phenylindole and observed under fluorescence
Figure 3 Detection of aloin-mediated apoptosis in human non-small cell cancer cells. Cells were treated with 100mM or 200mM
aloin and the apoptotic cells of (A) A549 and (B) H1299 cells were assessed by flow cytometry with Annexin-V/propidium iodide
double staining.
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Figure 4 Autophagy induced by aloin in human non-small-
cell lung cancer cells. Cells were treated with 100mM or
200mM aloin for 72 hours and the expression of LC3 was
detected by Western blotting. Beta-actin was used as a loading
control. Two independent experiments were carried, but only
one is shown here.
148 M.-C. Lee et al.apoptosis and suppressed autophagy. The decreased
expression of LC3-II in H1299 cell lines requires further
investigation.
Discussion
We have shown the cytotoxic effects of aloin on human
NSCLC cells (Fig. 1). The aloin-induced phenomenon of
multinucleated cells is similar to previous observations in
breast and ovarian tumor cells12 and was also observed in
human NSCLC cells (Fig. 2). Compared with the H1299 cells,
A549 cells are more susceptible to growth inhibition by
aloin.
Aloin-induced apoptosis has been reported in several
human cancer cell lines.10e13 In this study, aloin was shown
to induce a high percentage of apoptotic cells in the A549
cell line. Interestingly, the aloin-induced apoptosis of A549
cells is higher than that of H1299 cells (Figs. 3A and 3B).
A549 contains wild type p53 and H1299 contains null dele-
tion p53. The involvement of p53 in aloin-induced apoptosis
in human NSCLC cells therefore needs further investigation.
Recent reports have suggested that stress stimulates the
autophagy process to adapt to changes in the surroundings.
When the stress is above the survival threshold, cells will
shift to an apoptotic process. If the apoptotic process is
initiated, the autophagy program will stop.23 In the A549
cell line, the lower concentration of aloin (100mM) treat-
ment consistently induced a higher level of expression of
LC3-II and the apoptotic cells did not significantly increase.
Furthermore, the IC50 concentration of aloin (200mM) pro-
moted apoptosis and suppressed the expression of LC3-II. In
addition, the cellular location of the p53 protein regulates
autophagy.23 The cytosolic portion of p53 restrains auto-
phagosome formation; however, the nuclear portion of p53
activates many genes to adapt to environmental stress.23
Under lethal conditions, p53 will translocate to the mito-
chondria to influence the permeability transition of the
mitochondria and to eliminate any dysfunctional mito-
chondria.23 In the H1299 cell line, which contains the null
mutation p53 gene, the expression of LC3-II was reduced in
a concentration-dependent manner. Therefore the role
played by p53 in aloin-induced autophagy in human NSCLC
cells should be investigated further.
We have shown the in vitro antitumor effects of aloin on
human NSCLC cells through the formation of multinuclear
cells, apoptosis, and/or autophagy. A549 cells are moresusceptible to the cytotoxic effects of aloin than H1299
cells. Aloin may be a potential therapeutic agent against
human NSCLCs and is worthy of further investigation.
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